Discovery and Validation of a Six-Marker Serum Protein Signature for the Diagnosis of Active Pulmonary Tuberculosis
Open Access
- 1 October 2017
- journal article
- research article
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 55 (10), 3057-3071
- https://doi.org/10.1128/jcm.00467-17
Abstract
New non-sputum biomarker tests for active tuberculosis (TB) diagnostics are of the highest priority for global TB control. We performed in-depth proteomic analysis using the 4,000-plex SOMAscan assay on 1,470 serum samples from seven countries where TB is endemic. All samples were from patients with symptoms and signs suggestive of active pulmonary TB that were systematically confirmed or ruled out for TB by culture and clinical follow-up. HIV coinfection was present in 34% of samples, and 25% were sputum smear negative. Serum protein biomarkers were identified by stability selection using L1-regularized logistic regression and by Kolmogorov-Smirnov (KS) statistics. A naive Bayes classifier using six host response markers (HR6 model), including SYWC, kallistatin, complement C9, gelsolin, testican-2, and aldolase C, performed well in a training set (area under the sensitivity-specificity curve [AUC] of 0.94) and in a blinded verification set (AUC of 0.92) to distinguish TB and non-TB samples. Differential expression was also highly significant (P < 10−20) for previously described TB markers, such as IP-10, LBP, FCG3B, and TSP4, and for many novel proteins not previously associated with TB. Proteins with the largest median fold changes were SAA (serum amyloid protein A), NPS-PLA2 (secreted phospholipase A2), and CA6 (carbonic anhydrase 6). Target product profiles (TPPs) for a non-sputum biomarker test to diagnose active TB for treatment initiation (TPP#1) and for a community-based triage or referral test (TPP#2) have been published by the WHO. With 90% sensitivity and 80% specificity, the HR6 model fell short of TPP#1 but reached TPP#2 performance criteria. In conclusion, we identified and validated a six-marker signature for active TB that warrants diagnostic development on a patient-near platform.Keywords
Funding Information
- Bill and Melinda Gates Foundation (OPP1039652)
This publication has 51 references indexed in Scilit:
- Trp’ing TuberculosisCell, 2013
- Elucidating Novel Serum Biomarkers Associated with Pulmonary Tuberculosis TreatmentPLOS ONE, 2013
- Plasma kallistatin levels in patients with severe community-acquired pneumoniaCritical Care, 2013
- Early Detection of Malignant Pleural Mesothelioma in Asbestos-Exposed Individuals with a Noninvasive Proteomics-Based Surveillance ToolPLOS ONE, 2012
- Serum Indoleamine 2,3-Dioxygenase Activity Predicts Prognosis of Pulmonary TuberculosisClinical and Vaccine Immunology, 2012
- Aptamer-Based Multiplexed Proteomic Technology for Biomarker DiscoveryPLOS ONE, 2010
- Stability selectionJournal of the Royal Statistical Society Series B: Statistical Methodology, 2009
- Starvation Survival Response of Mycobacterium tuberculosisJournal of Bacteriology, 2003
- A Direct Approach to False Discovery RatesJournal of the Royal Statistical Society Series B: Statistical Methodology, 2002
- Systematic Evolution of Ligands by Exponential Enrichment: RNA Ligands to Bacteriophage T4 DNA PolymeraseScience, 1990